

Prematurely ended - Statement

EudraCT Number: 2016-004825-17

Full title of the study: A Proof of concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy (PreTOPIC).

Sponsor-ID: preTopic17
Sponsor: Charité – Universitätsmedizin Berlin

Contact email address: carsten.tschöpe@charite.de

Product: Telbivudine, Sebivo®

Study Contact: Prof. Dr. Carsten Tschöpe, MD
Charité-University Medicine Berlin,
Campus Virchow-Klinikum (CVK)
Department of Cardiology

Date of early termination: 31.05.2020


Statement: Parvovirus B19 is a seasonal illness. During the PreTOPIC study recruitment period from December 6, to May 31, 2020, there was an epidemiologic reduction in the number of parvovirus B19-positive cases. Thus, only one patient with the required inclusion criteria could be recruited instead of 25 planned patients. The single subject was treated with telbivudine.

The small number of subjects analysed leading to unreliable data.

In May 2020 the decision was made for early termination of the preTOPIC study.

Signature/ Job role

Prof. Dr. Carsten Tschöpe / Principle investigator



.....